| Identification | More | [Name]
Felodipine | [CAS]
86189-69-7 | [Synonyms]
4-(2,3-DICHLOROPHENYL)-1,4-DIHYDRO-2,6-DIMETHYL-3,5-PYRIDINECARBOXYLIC ACID ETHYL METHYL ESTER
4-(2,3-DICHLOROPHENYL)-1,4-DIHYDRO-2,6-DIMETHYL-3,5-PYRIDINECARBOXYLIC ACID METHYL ESTER
4-(2,3-DICHLOROPHENYL)-1,4-DIHYDRO-2,6-DIMETHYL-3,5-PYRIDINEDICARBOXYLIC ACID METHYL ESTER
ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
FELODAY
FELODIPINE
FLODIL
PLENDIL
Felodipine | [Molecular Formula]
C18H19Cl2NO4 | [MDL Number]
MFCD00868316 | [Molecular Weight]
384.25 | [MOL File]
86189-69-7.mol |
| Hazard Information | Back Directory | [Uses]
Vasodilator. | [Brand name]
Plendil (AstraZeneca). | [Clinical Use]
Calcium-channel blocker:HypertensionAngina | [Drug interactions]
Potentially hazardous interactions with other drugs
Aminophylline and theophylline: possibly increased
aminophylline and theophylline concentration.
Anaesthetics: enhanced hypotensive effect.
Antibacterials metabolism possibly inhibited by
clarithromycin, erythromycin and telithromycin.
Antidepressants: enhanced hypotensive effect with
MAOIs.
Antiepileptics: effect reduced by carbamazepine,
barbiturates, phenytoin and primidone.
Antifungals: metabolism inhibited by itraconazole
and ketoconazole; negative inotropic effect possibly
increased with itraconazole.
Antihypertensives: enhanced hypotensive effect,
increased risk of first dose hypotensive effect of postsynaptic alpha-blockers.
Antivirals: concentration possibly increased by
ritonavir; use with caution with telaprevir.
Grapefruit juice: concentration increased - avoid
concomitant use.
Tacrolimus: possibly increased tacrolimus
concentration | [Metabolism]
Felodipine is metabolised in the liver and all identified
metabolites are devoid of vasodilating properties.
Approximately 70% of a given dose is excreted as
metabolites in the urine and about 10% with the faeces.
Less than 0.5% of the dose is excreted unchanged in the
urin |
|
|